Taken together, these studies have identified previously unknown components of the signaling cascade triggered by α-syn, therefore suggesting that PrPC signaling might be involved in the pathogenesis of synucleinopathies and may be used as a potential therapeutic target to prevent or slow down the progression of synucleinopathies. This evidence concerns the gene PRNP and synucleinopathy.